Heteroaryl-pyrazole derivatives as cannabinoid CB1 receptor antagonists
申请人:Green Cross Corporation
公开号:US07875647B2
公开(公告)日:2011-01-25
A heteroaryl-pyrazole compound of formula (I) or a pharmaceutically acceptable salt thereof is effective as a cannabinoid CB1 receptor inverse agonist or antagonist, which is useful for preventing or treating obesity and obesity-related metabolic disorders. The present invention also provides a method for preparing the inventive heteroaryl-pyrasole compounds or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing same, and a method for preventing or treating obesity and obesity-related metabolic disorders.
Heteroaryl-Pyrazole Derivatives as Cannabinoid CB1 Receptor Antagonists
申请人:LEE Jinhwa
公开号:US20080081812A1
公开(公告)日:2008-04-03
A heteroaryl-pyrazole compound of formula (I) or a pharmaceutically acceptable salt thereof is effective as a cannabinoid CB
1
receptor inverse agonist or antagonist, which is useful for preventing or treating obesity and obesity-related metabolic disorders. The present invention also provides a method for preparing the inventive heteroaryl-pyrasole compounds or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing same, and a method for preventing or treating obesity and obesity-related metabolic disorders.